Security key
867781403
Sunshine Biopharma Inc. - Common Units, $ 0.001 par value (SBFM)
CUSIP: 867781403
Q2 2022 13F Holders as of 30 Jun 2022
- Security type / class
- Equity / Common Units, $ 0.001 par value
- Total 13F shares
- 735,073
- Total 13F value
- $800,085
- Share change
- -733,147
- SEC-reported price per share
- $1.08
- Number of holders
- 12
- Value change
- -$2,673,546
- Number of buys
- 9
- Number of sells
- 6
- Shares outstanding
- 17,152,659
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2022
Institutions
12
Top holders
10
SBFM full security history
Ownership snapshot
Full 13F holder table
Sunshine Biopharma Inc. SEC filings
Sunshine Biopharma Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of SBFM - Sunshine Biopharma Inc. - Common Units, $ 0.001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
ARMISTICE CAPITAL, LLC
Comparable rows
0/15
Latest evidence
31 Mar 2022
13F
3/4/5
Highest disclosed value: $2,432,000
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
ARMISTICE CAPITAL, LLC has the largest disclosed position value at $2.43M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Disclosed position value
Top 5
ARMISTICE CAPITAL, LLC
$2.43M
Empery Asset Management, LP
$1.34M
Hudson Bay Capital Management LP
$779K
Rabi Kiderchah
$248.1K
James Daniel Kish
$221.1K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13F
Company
|
—
mixed-class rows
|
$2,432,000
1,519,602 shares
mixed-class rows
|
— | 31 Mar 2022 |
| Empery Asset Management, LP |
13F
Company
|
—
mixed-class rows
|
$1,337,000
685,650 shares
mixed-class rows
|
— | 31 Mar 2022 |
| Hudson Bay Capital Management LP |
13F
Company
|
—
mixed-class rows
|
$779,000
375,000 shares
mixed-class rows
|
— | 31 Mar 2022 |
| Rabi Kiderchah |
3/4/5
Director
|
—
denominator unverified
|
$248,138
325,000 shares
|
— | 31 Oct 2021 |
| James Daniel Kish |
3/4/5
Director
|
—
denominator unverified
|
$221,110
289,600 shares
|
— | 31 Oct 2021 |
| CVI Holdings, LLC |
13F
Company
|
—
denominator unverified
|
$74,000
74,632 shares
|
— | 31 Mar 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2022
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
12
Shares
735,073
Rows available
12
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2022 vs Q1 2022 Across Filers
Q1 2022 holders
12
Q2 2022 holders
12
Holder diff
0
| Investor | Q1 2022 Shares | Q2 2022 Shares | Share Diff | Share Chg % | Q1 2022 value | Q2 2022 value | Value change | Value Chg % |
|---|